The potentially deadly fungal infection — identified in the U.S. for the first time last year — is an emerging pathogen with the capacity to develop antifungal-resistant biofilms, which could potentially adhere to medical instruments. The yeast has displayed resistance to all three major classes of antifungal medications.
To determine the yeast’s susceptibility to disinfectants, researchers tested seven antifungal agents: fluconazole, voriconazole, caspofungin, micafungin, liposomal amphotericin B, amphotericin B and chlorhexidine. While amphotericin B also displayed efficacy, chlorhexidine proved most effective in inhibiting the yeast’s biofilm growth.
“We showed that chlorhexidine is effective against C. auris planktonic and sessile communities. Thus, use of this disinfectant can be advocated for topical control of C. auris at standard concentrations used for skin and wound cleansing and disinfection. Infection-prevention measures targeting C. auris biofilms in patients, on medical devices and in the hospital environment will be required,” concluded the study’s authors.
More articles on infection control:
King County, Wash., mumps outbreak up to 130 cases
New subtype of cervical cancer linked to HPV identified
Michigan Medicine earns $2M grant for study on germ-killing robots
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.